David McClung's Insider Trades & SAST Disclosures
David McClung's most recent trade in BioCardia Inc. was a trade of 24,193 Common Stock done at an average price of $2.6 . Disclosure was reported to the exchange on Oct. 11, 2024.
Add Superstar Alert
Note
This is a custom search result for pattern David McClung.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.65 per share. | 11 Oct 2024 | 24,193 | 41,573 (0%) | 0% | 2.6 | 64,111 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 11 Oct 2024 | 11,565 | 30,008 (0%) | 0% | 2.6 | 30,647 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 03 Sep 2024 | 8,333 | 17,380 (0%) | 0% | 3 | 24,999 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 8,333 | 8,333 | - | - | Warrant (right to buy) | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.77 per share. | 25 Aug 2023 | 1,925 | 214,396 (0%) | 0% | 0.8 | 1,482 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 25 Jun 2023 | 11,528 | 211,321 (0%) | 0% | 1.2 | 13,718 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.34 per share. | 23 Jun 2023 | 4,280 | 135,724 (1%) | 0% | 2.3 | 9,998 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 31 May 2023 | 20,676 | 131,444 (1%) | 0% | 1.8 | 36,597 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 25 May 2023 | 1,925 | 222,849 (0%) | 0% | 1.3 | 2,560 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 68,265 | 68,265 | - | - | Stock Option (right to buy) | |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.70 per share. | 18 May 2023 | 61,389 | 152,120 (2%) | 0% | 1.7 | 104,361 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 56,250 | 234,519 (0%) | 0% | 0 | Common Stock | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 24 Feb 2023 | 9,745 | 224,774 (0%) | 0% | 2.7 | 25,922 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.68 per share. | 16 Dec 2022 | 8,928 | 87,446 (1%) | 0% | 1.7 | 14,999 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.07 per share. | 10 Oct 2022 | 2,000 | 78,518 (1%) | 0% | 2.1 | 4,140 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.31 per share. | 25 Jun 2022 | 11,525 | 175,816 (0%) | 0% | 4.3 | 49,673 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.32 per share. | 12 May 2022 | 20,632 | 76,518 (1%) | 0% | 1.3 | 27,234 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 50,345 | 97,150 (1%) | 0% | 0 | Common Stock | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 160,380 | 160,380 | - | - | Stock Option (Right to Buy) | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 59,400 | 184,984 (0%) | 0% | 0 | Common Stock | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.90 per share. | 25 Feb 2022 | 4,610 | 125,584 (0%) | 0% | 5.9 | 27,199 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.02 per share. | 25 Jun 2021 | 11,525 | 129,294 (0%) | 0% | 12.0 | 138,531 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.35 per share. | 10 Jun 2021 | 7,274 | 46,805 (0%) | 0% | 4.4 | 31,642 | Common Stock |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 75,850 | 75,850 | - | - | Stock Option (right to buy) | |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,370 | 54,079 (0%) | 0% | 0 | Common Stock | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 40,000 | 140,000 (0%) | 0% | 0 | Common Stock | |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 30 Jun 2020 | 7,895 | 32,709 (0%) | 0% | 2.4 | 18,948 | Common Stock |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
|
Sangamo Therapeutics Inc
|
David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
|
BioCardia Inc.
|
David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 19,312 | 40,604 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges